Sarepta, Biogen drugs with accelerated approval under fire in FDA report
A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says
Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed ...
BioSpace1d
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...
BioSpace22h
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.
Temporary Revenue Surge and Market Penetration Concerns Lead to Sell Rating for Sarepta Therapeutics
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...
Becker's Hospital Review20h
Watchdog flags flaws in FDA's fast-track drug approvals
The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional ...
precisionmedicineonline1d
OIG Recommends Changes in FDA Accelerated Approval After Flagging Concerns With Aduhelm, Other Drugs
The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.
Sarepta Therapeutics: Strong Financial Performance and Promising Growth Prospects Justify Buy Rating
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating yesterday.Stay Ahead of the ...
kffhealthnews1d
After 2 Deaths, Philips Recalls Software That Mishandled Some EKG Readings
Another 109 people reported injuries after using the remote cardiac monitoring software, Modern Healthcare reported. Other pharmaceutical and tech news is on the FDA's drug approval system and a rapid ...
Reuters26d
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Dec 20 - Japanese drugmaker Nippon Shinyaku (4516.T), opens new tab infringed a Sarepta (SRPT.O), opens new tab patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay ...
The Business Journals24d
Three Kendall Square buildings sold to lab heavyweight for $250M
The properties include the headquarters for Sarepta Therapeutics and Editas Medicine. Blackstone and its affiliate, BioMed Realty, have paid $250 million to Alexandra Real Estate Equities Inc. to ...